CB2 Insights (CSE:CBII, OTCQB:CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today announced that MyAccess Clinics (“MAC”) has selected CB2 Insights’ Electronic Data Capture (EDC) software to manage patient data within its growing number of medical clinics in the UK. MyAccess Clinics is a wholly-owned subsidiary of leading global medical cannabis company, Althea Group Holdings Ltd (ASX:AGH).
“The UK market continues to blossom at a rapid pace, and we are proud that our research and data technology assets continue to be sought to expedite growth in the market,” said Prad Sekar, Chief Executive Officer, CB2 Insights. “MyAccess Clinics has an exceptional and comprehensive vision for its development in the UK’s medical cannabis market and we are excited to be a part of that effort.”
CB2 Insights’ EDC software has been used throughout the US and Canada and uses standard healthcare protocols. The system is purpose-built for medical cannabis operations and takes into account the complexity of managing data related to multiple indications across a single patient base, comorbidity in certain patient profiles, past traditional therapies and multiple consumption methods and medicine within a single treatment plan. The system works to simplify data input and management while ensuring collection can ultimately be used to better understand the efficacy of cannabinoid therapy. This deployment will increase both the size and scope of the Company’s data set.
Graham Woodward, MyAccess Clinics Clinical Director said “As a company, we are proud to be one of the first to service the emerging UK medical cannabis market. CB2 Insights’ software will play an integral part in the administration of our clinics and will increase our ability to manage data, thereby improving our patient care.”
Earlier this year, CB2 Insights announced that it had been selected as the exclusive research technology platform for UK-based Drug Science and its medical cannabis pilot program.
About CB2 Insights
CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare. We are a research and technology company, offering a suite of data and technology solutions as a full service clinical CRO, specializing in Phase II, III and IV, post-marketing, observational and experimental trials in a range of therapeutic areas for sponsors worldwide.
CB2 Insights helps industry stakeholders create a strong value story with Real World Evidence, generation of safety and efficacy data, operating in two segments: clinical solutions and data solutions.
For more information please visit www.cb2insights.com.
About MyAccess Clinics
MyAccess Clinics provide expert care for patients with unmet needs, which licensed medicines have failed to address, through the use of ‘specials’ medicines. ‘Specials’ are unlicensed medicines that are specifically manufactured or obtained in order to meet a patient’s individual clinical need. An example of this would be unlicensed cannabis-based products for medicinal use, which our private clinics specialize in.
MyAccess Clinics is a wholly-owned subsidiary of leading global medical cannabis company, Althea Group Holdings Ltd (ASX:AGH).
For more information please visit https://myaccessclinics.co.uk/
For additional information, please contact:
Dan Thompson – CB2 Insights
1.855.847.4999 ext 120
Julia Maguire – Althea Group / The Capital Network
+61 419 815 386
Forward Looking Statements
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CB2’s filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.
Forward-looking statements may include, without limitation, statements regarding the opportunity to provide services and software to the U.S. cannabis industry.
Although CB2 has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry and; regulatory or political change.
There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.
Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CB2 disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CB2 does not assume any liability for disclosure relating to any other company mentioned herein.
No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.
Find out what experts say about profiting from the cannabis market in 2021!
Read our FREE 2021 cannabis outlook report!